Subscribe: Clinical Trials / Drug Trials News From Medical News Today
Added By: Feedage Forager Feedage Grade A rated
Language: English
cancer drug  cancer  clinical trial  clinical trials  clinical  drug  new  patients  phase  results  study  survival  trial 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Clinical Trials / Drug Trials News From Medical News Today

Clinical Trials / Drug Trials News From Medical News Today

Clinical trials are a type of research study to explore whether a medical treatment, drug, strategy or device is safe and effective for human use. The purpose of clinical trials is research, so the studies follow strict scientific standards. These standar

Copyright: Copyright 2016 Medical News Today

Additions to standard multiple myeloma therapy do not appear to yield additional benefit

Thu, 08 Dec 2016 00:00:00 PST

Largest randomized trial finds second round of chemotherapy or stem cell transplant does not improve progression-free survival.

New data shed light on potential advantages of pacritinib for patients with myelofibrosis

Thu, 08 Dec 2016 00:00:00 PST

Pacritinib, currently on hold by the FDA, appears to be more effective in reducing spleen volume; twice-daily dose improves symptoms - this analysis comes from data before the clinical hold.

Cancer drug ibrutinib found helpful in treating graft versus host disease after transplant

Thu, 08 Dec 2016 00:00:00 PST

Ibrutinib could be promising new option for patients who don't respond to corticosteroid treatment.

Experimental drug for spinal muscular atrophy shows promising early results, prompting phase 3 clinical trial

Wed, 07 Dec 2016 06:00:00 PST

A new drug for spinal muscular atrophy has shown promising early results in a phase 2 trial involving 20 babies with infantile-onset spinal muscular atrophy.

Combination immune therapy shows promise against Hodgkin lymphoma

Tue, 06 Dec 2016 06:00:00 PST

The combination of two new drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to...

Nivolumab with chemotherapy improves response, survival in AML study patients

Tue, 06 Dec 2016 06:00:00 PST

The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled response rates and improved overall survival in patients with acute myeloid leukemia (AML), according to...

Phase I trial shows that a drug that inhibits the Notch signalling process is active in a range of advanced cancers

Mon, 05 Dec 2016 00:00:00 PST

A new anti-cancer drug that inhibits a key cell signalling process involved in many different cancers has shown that it is capable of stopping the progression of cancer and shrinking tumours.

Advanced soft tissue sarcomas respond to a combination of a new and an existing anti-cancer drug

Mon, 05 Dec 2016 00:00:00 PST

Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory...

Alzheimer's: Are we on the right path to new drugs?

Wed, 30 Nov 2016 08:00:00 PST

Following the news that Alzheimer's drug solanezumab has failed clinical trials, we look at whether researchers are on the right track for new treatments

Eli Lilly Alzheimer's drug fails to show benefits in final stage clinical trial

Thu, 24 Nov 2016 06:00:00 PST

Eli Lilly and Company has announced that their drug solanezumab has failed to meet its primary endpoint of slowing cognitive decline in people with mild Alzheimer's disease.

Rheumatoid arthritis drugs - direct switch has a beneficial effect

Wed, 16 Nov 2016 06:00:00 PST

For the first time, a multicentre study headed up by MedUni Vienna has compared the action of two rheumatoid arthritis drugs from the same class.

Phase 3 Bridge study showed romosozumab significantly increased bone mineral density in men with osteoporosis

Tue, 15 Nov 2016 06:00:00 PST

UCB and Amgen have announced results from the Phase 3 BRIDGE study showing that in men with osteoporosis, the investigational agent romosozumab resulted in significant bone mineral density (BMD)...

Take multiple biopsies in studies of personalised breast cancer treatments, study says

Fri, 11 Nov 2016 06:00:00 PST

New research finds taking single biopsy can miss key genetic mutations that could influence drug susceptibility and resistance.

Case report on long-term survival of kidney cancer patients treated with AGS-003 individualized immunotherapy published

Mon, 07 Nov 2016 06:00:00 PST

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced...

Publication of positive Phase 1 study results for EB-101 gene therapy clinical trial for epidermolysis bullosa

Fri, 04 Nov 2016 07:00:00 PST

Abeona Therapeutics Inc. a clinical-stage biopharmaceutical company focused on delivering gene therapies for life-threatening rare diseases, announced that positive clinical trial results from the...

Alzheimer's disease: New analyses from Phase 3 studies showing clinical benefit of Tramiprosate

Thu, 27 Oct 2016 06:00:00 PST

Results published in The Journal of the Prevention of Alzheimer's Disease (JPAD) describe analyses of Phase 3 data for the investigational amyloid-targeted drug, tramiprosate, in patients with Mild...

Reshaping the future of global clinical trials practice

Mon, 24 Oct 2016 00:00:00 PST

Researchers at the University of Liverpool have developed a new international guideline to help standardise how results from clinical trial studies are reported.

Investigational immunotherapy was safe, tolerable, and showed some activity against melanoma

Fri, 21 Oct 2016 00:00:00 PST

The investigational immunotherapeutic IMC-20D7S was safe, well tolerated, and showed signs of modest clinical activity for patients with advanced melanoma, according to results from a...

Positive pivotal Phase 3 data announced demonstrating investigational Elagolix reduced endometriosis-associated pain

Thu, 20 Oct 2016 05:00:00 PST

AbbVie, a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc.

Depression could be treated with anti-inflammatory drugs

Tue, 18 Oct 2016 08:00:00 PST

A new meta-analysis finds a new class of drugs used to treat inflammation in autoimmune diseases may also be an effective treatment for depression.

The placebo effect: Knowingly taking sham pills may reduce chronic pain

Mon, 17 Oct 2016 09:00:00 PST

New study suggests it is not the expectation that a 'dummy pill' is real that elicits the placebo effect, but rather the ritual associated with taking it.

Caffeine did not induce arrhythmia in trial with heart failure patients

Mon, 17 Oct 2016 08:00:00 PST

A trial where heart failure patients ingested 500 mg caffeine over 5 hours found no raised risk of arrhythmic episodes, even during treadmill stress test.

Breast cancer drug shows potential in patients with skin metastases

Fri, 14 Oct 2016 00:00:00 PST

A study presented at the ESMO Congress reveals how the drug tucatinib led to a reduction in skin metastases for patients with breast cancer.

Cabozantinib improves progression-free survival in metastatic renal cell carcinoma

Wed, 12 Oct 2016 05:00:00 PST

Cabozantinib significantly improves progression-free survival and response rate in patients with metastatic renal cell carcinoma compared to sunitinib, according to research presented at the ESMO...

Custirsen shows no survival benefits in metastatic prostate cancer

Wed, 12 Oct 2016 00:00:00 PST

A phase III randomized controlled trial of custirsen in combination with cabazitaxel/prednisone in patients with previously-treated metastatic, castration-resistant prostate cancer has shown no...